Precision Medicine in Gynaecological Oncology

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 2043

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Surgery, Medicine, Dentistry and Morphological Sciences with Interest in Transplantation, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
2. Department of Laboratory Medicine and Anatomical Pathology, University Hospital of Modena—Polyclinic, Modena, Italy
Interests: pathology oncology gynecology; human papilloma virus (HPV); epstein–barr virus (EBV); human herpes virus 8 (HHV8); coronavirus disease 2019 (COVID-19); severe acute respiratory syndrome (SARS); middle east respiratory syndrome (MERS); nipah virus ebola virus
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Medical practice is fully immersed in the era of precision medicine by means of predictive techniques and bioinformatics applied to solid or liquid biopsies. Advances in our understanding of molecular alterations in various malignancies have allowed for the development of ever finer diagnoses, effective targeted therapies, and the prediction of accurate prognoses in the setting of modern immunotherapies. Besides histopathology combined with molecular diagnostics, pretargeting for imaging and therapy is gaining consensus in oncological nuclear medicine. Today, gynecological oncology can be considered to all effects an ultra-specialized branch enriched by clinical-pathological correlations, not only for the ascertained role of the Human Papilloma Virus (HPV) in oncogenesis and the consequent introduction of HPV-test in cervical cancer screening next to PAP-smear, but also for the broad availability of diagnostic, prognostic and predictive immunohistochemistry, and for the possibility of genomic profiling in female tumors through next-generation sequencing. The aim of this Special Issue is to highlight the latest advances in the comprehensive context of precision medicine in gynecological oncology.

Dr. Luca Roncati
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynaecological oncology 
  • gynaecological pathology 
  • precision medicine 
  • personalized oncology 
  • targeted therapy 
  • immunotherapy 
  • predictive immunohistochemistry 
  • next-generation sequencing 
  • liquid biopsy 
  • bioinformatics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 261 KiB  
Article
Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia
by Dora Čerina, Višnja Matković, Kristina Katić, Ingrid Belac Lovasić, Robert Šeparović, Ivana Canjko, Žarko Bajić and Eduard Vrdoljak
J. Pers. Med. 2022, 12(7), 1176; https://doi.org/10.3390/jpm12071176 - 19 Jul 2022
Viewed by 1569
Abstract
Today, in the era of precision medicine, the determination of genomic instability or other potentially targetable mutations, along with BRCA 1 and BRCA 2, is a crucial component of the diagnosis and treatment management of advanced ovarian cancer. Advanced technologies such as next-generation [...] Read more.
Today, in the era of precision medicine, the determination of genomic instability or other potentially targetable mutations, along with BRCA 1 and BRCA 2, is a crucial component of the diagnosis and treatment management of advanced ovarian cancer. Advanced technologies such as next-generation sequencing (NGS) have enabled comprehensive genomic profiling (CGP) analysis to become more feasible for routine use in daily clinical work. Here, we present the results for the first two years of an analysis of patients with advanced ovarian cancer on a national level. The aim was to establish the position of CGP in the daily clinical practice of treating ovarian cancer. We performed a multicenter, retrospective, cross-sectional analysis on the total population of Croatian patients who were newly diagnosed with locally advanced or metastatic ovarian cancer or whose initial disease had progressed from 1 January 2020 to 1 December 2021, and whose tumors underwent CGP analysis. All 86 patients (100%) analyzed with CGP had at least one genomic alteration (GA). The median LOH was 14.6 (IQR 6.8–21.7), with 35 patients (41%) having an LOH ≥ 16. We found BRCA-positive status in 22 patients (26%). Conventional testing, which detects only BRCA mutations, would have opted for therapy with PARP inhibitors in 22 (26%) of our patients. However, CGP revealed the need for PARP inhibitors in 35 patients (41%). The results identified a significantly higher number of women who would achieve a possible benefit from targeted therapy. Hence, we believe that CGP should be a backbone diagnostic tool in the management of ovarian cancer. Full article
(This article belongs to the Special Issue Precision Medicine in Gynaecological Oncology)
Back to TopTop